Companies › Optinose US
1 active drug program in 7 registered trials: 3 Phase 2, 2 Phase 3, 2 Phase 4; Immunology, Other, Respiratory; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fluticasone Propionate (OPN-375) Glucocorticoid receptor agonist | NR3C1 | Phase 3 | Chronic Rhinosinusitis Without Nasal Polyps; Allergic Rhinitis; Healthy; Chronic Cough … | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07415278 | Fluticasone Propionate (OPN-375) | Phase 4 | Allergic Rhinitis | Immunology | Oct 2023 |
| NCT02476825 | Fluticasone Propionate (OPN-375) | Phase 4 | Healthy | Other | Oct 2026 |
| NCT05275686 | Fluticasone Propionate (OPN-375) | Phase 2 | Eustachian Tube Dysfunction | Other | Jun 2027 |
| NCT07582549 | Fluticasone Propionate (OPN-375) | Phase 3 | Chronic Cough | Other | Dec 2027 |
| NCT03002389 | Fluticasone Propionate (OPN-375) | Phase 2 | Chronic Obstructive Pulmonary Disease | Respiratory | Jan 2028 |
| NCT06850805 | Fluticasone Propionate (OPN-375) | Phase 3 | Chronic Rhinosinusitis Without Nasal Polyps | Respiratory | Mar 2028 |
| NCT03742414 | Fluticasone Propionate (OPN-375) | Phase 2 | Eczema, Infantile | Immunology | May 2028 |
Oticara Australia Zhejiang Wenda Pharma Technology ReAlta Life Sciences Tiohundra Abivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.